Articles | September 21, 2021
DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). The trial has commenced enrollment and dosing of… Read More
Articles | September 15, 2021
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx’s conditionally approved graduation from the TSX… Read More
Articles | September 14, 2021
Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being… Read More
Articles | September 9, 2021
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy… Read More
Articles | September 3, 2021
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming investor conferences in September: Presentation details can be found below: Citi 16th Annual BioPharma Conference Format: Panel Discussion… Read More
Articles | August 16, 2021
Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company developing psychedelics and large pharma Advancement of 11 therapeutic programs, including initiation of Recognify’s Phase… Read More
Articles | August 12, 2021
atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences (Revixia), a wholly owned subsidiary developing Salvinorin A (SalA) to treat a variety of mental health disorders. Derived from… Read More
Articles | August 9, 2021
atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30,… Read More
Articles | August 6, 2021
atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity Growth Conference, to be held virtually from August 10-12, 2021. Read More
Articles | July 28, 2021
atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc. (InnarisBio),… Read More
JOIN THE ATAI #INSIGHTNETWORK